Pharvaris N.V. (PHVS)
Pharvaris N.V. operates in the Biotechnology industry of the Healthcare sector, headquartered in Leiden, ZH, NL. The stock last traded at $34.08, down 0.98% on the session, giving a market capitalisation of $2.38B. On trailing twelve-month figures it carries a trailing P/E of -10.42, a net margin of 0.0%. Its beta of -2.33 implies it has historically moved less than the broad market.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Pharvaris N.V. is most often compared with the following Healthcare names: